Generic cancer drug candidate put to the test
NCT ID NCT07694011
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study compares a new capsule form of pomalidomide (Xetrane) with the approved drug Imnovid in healthy male volunteers. The goal is to see if the two versions are absorbed and processed by the body in the same way. Participants receive a single dose of each capsule on separate days, and blood samples are taken to measure drug levels. The results will help determine if the new formulation can be used as a substitute for the original.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pomalidomide
- What this could lead to
- If the test capsule is shown to be equivalent, it could offer a more affordable or accessible alternative to the current drug.
- What could go wrong
- This is an early-stage bioequivalence study in healthy volunteers, not patients. Even if equivalent, it does not prove safety or effectiveness for treating disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POMALIDOMIDE BIOEQUIVALENCE STUDY IN HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Domínguez Lab
Santiago, Providencia, Chile